Ilan Hadar

CIK 1727727 · Chairman and CEO · last filed 2026-06-08

Ilan Hadar is a Chairman and CEO who has filed 9 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for SLXNW, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$153.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $415 across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$415

Companies

3

Total Filings

9

Lifetime Open-Market Net

-$153.4K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SLXNW Chairman and CEO 16,547 $0.03 $415 $0 2 2026-06-08
VYNE Therapeutics Inc. (MNLO) Delisted CFO and Country Manager 8,339 $0 1 2020-03-11
Foamix Pharmaceuticals Ltd. (FOMX) Delisted CFO & Country Manager 130,578 -$153.4K 5 2020-02-24

Recent Filings

9 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-06-08 SLXNW Grant (A) +10,000 $0 EDGAR
2026-02-23 SLXNW Grant (A) +64,350 $0 EDGAR
2020-03-11 Disp (D) −130,578 $0
2020-03-11 VYNE Therapeutics Inc. (MNLO) Delisted Grant (A) +77,351 $0 EDGAR
2020-02-24 Foamix Pharmaceuticals Ltd. (FOMX) Delisted Grant (A) +41,299 $0 EDGAR
2019-09-11 Foamix Pharmaceuticals Ltd. (FOMX) Delisted Sell (S) −43,812 -$153.4K EDGAR
2019-01-03 Foamix Pharmaceuticals Ltd. (FOMX) Delisted Grant (A) +40,712 $0 EDGAR
2018-02-28 Foamix Pharmaceuticals Ltd. (FOMX) Delisted Grant (A) +11,698 $0 EDGAR
2018-01-24 Foamix Pharmaceuticals Ltd. (FOMX) Delisted Exer (M) +5,594 $0 EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.